The Action of Mendelian Genes in Human Diploid Cell Strains '

Total Page:16

File Type:pdf, Size:1020Kb

The Action of Mendelian Genes in Human Diploid Cell Strains ' The Action of Mendelian Genes in Human Diploid Cell Strains ' ROBERT S. KROOTH AND ELIZABETH K. SELL2 Lawrence D. Buhl Center for Human Genetics, Department of Human Genetics, University of Michigan Medzcal School, Ann Arbor, Michigan 48104 ABSTRACT Some of the cells of every human being will grow outside the body as microorganisms. It is possible to show, in a variety of ways, that these cells resemble genetically the individual from whom they were obtained. Over 35 inherited human diseases and anomalies can now be studied in such cell lines. Human diploid cell strains, biochemically marked by one or more mutant Mendelian genes, have proven particularly useful for the study of gene action in man and for the detection of genetic changes such as mutation and somatic cell hybridization. In addition, the strains have a number of clinical applications, including the antenatal diagnosis of inherited disease. The failure of cultured human cells to display their phenotype at most loci continues to restrict their use in both genetics and medicine. There are reasons for hoping that this difficulty will eventually be solved, and some experiments bearing on the problem are already feasible. To study genetics, one must start with to the isolation of a variant subline; in this hereditary variation. In cell culture, this case as well as in several others, an en- means one must have, as a minimum, two zyme deficiency is associated with the abil- different strains of cells which differ from ity of the cell to survive in the selective one another in at least one attribute. More- medium. Indeed, there are several general over, the difference must be hereditary over methods for preferentially favoring the somatic generations. growth of auxotrophic mammalian cells The initial problem of human cell gene- (Hooper and DeMars, '60; Kao and Puck, tics, therefore, has been to identify or gen- '68; Pollack, Green and Todaro, '68). Most erate this kind of variation. Two principal such auxotrophs may be presumed to be methods have been used to obtain lines of deficient in one or more enzyme activities. human cells that have some distinctive The second method for obtaining variant and hereditary attribute. The first method lines of human cells is quite different. One is to select infrequent cells, from a popu- begins by selecting donors (rather than lation which differs in a known way from cells) who are known to carry genes which the majority of the cells. For example, affect molecules normally present in cul- nearly all cells exposed to the synthetic tured cells (Krooth and Weinberg, '61). analogue 8-azaguanine are killed by this The Mendelian basis for the cellular pheno- agent, but, over a wide range of doses, a type is shown by developing strains from few are not (Szybalski and Szybalska, '62; various persons in the same family. inter aliae). The surviving cells are resist- There are important differences between ant to the drug, even if they are grown in the first and second method. In the first its absence for an extended period of time. method, the variant line and the line with In most cases, the resistant subline is de- which it is compared usually come from ficient in an enzyme which apparently con- the same donor. In the second method, the verts 8-azaguanine to the corresponding donors are different. It can be argued that ribotide (Brockman et al., '61; inter aliae). variants isolated by the first method are It is likely to be this ribotide, rather than 1 The originaI investisations reported in this paper the free base, which is cytotoxic. In any were supported by NIH Research grant 1-Pol-15419-03. 2 Supported by NIH Training grant 5-TOl-GM-00071- case, such an experiment frequently leads 13. J. CELL. PHYSIOL.,76: 311-330. 311 312 ROBERT S. KROOTH AND ELIZABETH K. SELL likely to differ from the parental line at cell is probably related to the biology of only a single locus. On the other hand, the cells. Since homonuclear cells, unlike when a variant isolated by the second heteronuclear ones, usually do not clone method is compared with a strain isolated with high efficiency, it can be difficult to from a normal donor, the two strains prob- select an infrequent cell from the popula- ably differ at many loci, for the genetic tion. The variant cell may not be able to polymorphisin of human populations is generate a colony when all the other cells very rich (Harris, '66; Lewontin, '67). The have been eliminated by the selective sys- advantage of the second method of course tem. Human heteronuclear lines, though is that one can prove by family studies that the cell attribute is hereditary over the they usually can be cloned with high ef- germ line, as well as over the somatic one. ficiency, are rarely isolated. Hence, the From such studies, one' can frequently con- probability of developing a heteronuclear clude that the attribute is controlled within line from a donor of an appropriate geno- each family by a single locus. If cell strains type is small. from several different unrelated patients A disappointing feature of cultured hu- all differ from normal strains in the same man cells is that they do not usually per- way, one can argue that normal variation form the tissue-specific functions of the at loci other than the one being studied is organ from which they were isolated. The irrelevant. reason for this phenomenon is unknown, As a rule, each method involves the use and a detailed discussion of the matter is of a different kind of cell. The first method outside the limits of this review, However, has been used successfully with heteronu- it seems likely that there are at least two clear cell lines, while the second method separate mechanisms involved. In the case employs homonuclear lines. The contrast- of human heteronuclear lines, the apparent ing properties of these two kinds of cell failure of the cells to perform tissue-speci- lines have been reviewed elsewhere fic functions may be related to the ana- (Krooth, Darlington and Velazquez, '68). plasia of the carcinomas from which they Their main features, which are relevant were isolated. In addition, most human to this discussion, are as follows: Human heteronuclear lines appear to have been heteronuclear lines show marked variation developed from carcinomas of the cervix, from cell to cell in chromosome comple- and have not been tested for their ability ment, are capable of indefinite growth in to perform a biochemical function peculiar vitro, and usually clone with high em- to the uterine cervix. In the case of human ciency. Human heteronuclear lines are homonuclear cell lines, the mechanism rarely isolated. Indeed, recent evidence is likely to be different. These cells have a suggests that many of the lines commonly fusiform morphology and engage in the used in experiments. and thought to have de novo synthesis of collagen (Green, independent origins, may in fact all be Goldberg and Todaro, '66) and mucopoly- derived from a single donor (Gartler, '67). saccharides (Fratantoni et al., '68). Hence, Most human heteronuclear lines seem to it seems likely that they are descended have been isolated from tissue involved in from the fibroblasts of intact tissues. Ap- a cancerous process. parently, with existing methods only this Human homonuclear lines, on the other type of human cell is capable of sustained hand, usually show very little variation growth in culture - at least in the case of from cell to cell in chromosome comple- normal solid tissues biopsied subsequent to ment - no more than is found in most in- birth. Perhaps the same is true of other tact tissues. They grow in vitro for only animals. The type of cell recovered in cul- about six months to a year, and are dif- ture seems surprisingly independent of the ficult to clone with high efficiency except organ whose tissue is sampled. Hence, it is perhaps very shortly after their isolation likely that the human cell which grows in from the explant. An important feature vitro is a fibroblast - a stromal element of homonuclear lines is that they can easily a It must be emphasized that the rules which govern be developed from virtually any don~r.~ the biology of cultured human cells do not necessarily The reason that the two methods have apply to the cells of other mammalian species (Todaro and Green, 63; Green and Todaro, '63; Bayreuther, each been used with a different kind of 64; Herzenberg, '64). MENDELIAN GENES IN HUMAN DIPLOID CELL STRAINS 313 which is ubiquitous. It is present in all or- duria (Krooth, '64b,'66a), citrullinemia gans but is the characteristic cell in none.4 (Tedesco and Mellman, '67), arginosuc- When we began to study gene action in cinic aciduria (Shih, Littlefield and Moser, human diploid cells, we tentatively formu- '69) and the Lesch-Nyhan Syndrome (Felix lated a rule that if an enzyme or other and DeMars, '69; Siniscalco et al., '69; inter molecule were ubiquitous -if it were aliae). In the case of this latter condition, present in all tissues - it would be found a medium which will select in favor of mu- in cultured homonuclear cells. The pres- tant homozygous cells, and against normal ence of the molecule would presumably cells, has also been developed (Albertini then not depend on which way the cell had and DeMars, '70). differentiated (Krooth and Weinberg, '61; Krooth, '65). In practice, no enzyme has Examples of gene action in diploid been studied in all tissues, and we used the cell strains rule-of-thumb that if the enzyme were a.
Recommended publications
  • DNA Polymerase Exchange and Lesion Bypass in Escherichia Coli
    DNA Polymerase Exchange and Lesion Bypass in Escherichia Coli The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Kath, James Evon. 2016. DNA Polymerase Exchange and Lesion Bypass in Escherichia Coli. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:26718716 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA ! ! ! ! ! ! ! DNA!polymerase!exchange!and!lesion!bypass!in!Escherichia)coli! ! A!dissertation!presented! by! James!Evon!Kath! to! The!Committee!on!Higher!Degrees!in!Biophysics! ! in!partial!fulfillment!of!the!requirements! for!the!degree!of! Doctor!of!Philosophy! in!the!subject!of! Biophysics! ! Harvard!University! Cambridge,!Massachusetts! October!2015! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ©!2015!L!James!E.!Kath.!Some!Rights!Reserved.! ! This!work!is!licensed!under!the!Creative!Commons!Attribution!3.0!United!States!License.!To! view!a!copy!of!this!license,!visit:!http://creativecommons.org/licenses/By/3.0/us! ! ! Dissertation!Advisor:!Professor!Joseph!J.!Loparo! ! ! !!!!!!!!James!Evon!Kath! ! DNA$polymerase$exchange$and$lesion$bypass$in$Escherichia)coli$ $ Abstract$ ! Translesion! synthesis! (TLS)! alleviates!
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0158968 A1 Panitch Et Al
    US 20100158968A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0158968 A1 Panitch et al. (43) Pub. Date: Jun. 24, 2010 (54) CELL-PERMEANT PEPTIDE-BASED Publication Classification INHIBITOR OF KINASES (51) Int. Cl. (76) Inventors: Alyssa Panitch, West Lafayette, IN st e8 CR (US); Brandon Seal, West ( .01) Lafayette, IN (US) A638/10 (2006.01) s A638/16 (2006.01) Correspondence Address: A6IP 43/00 (2006.01) GREENBERG TRAURIG, LLP (52) U.S. Cl. ................ 424/422:514/15: 514/13: 514/14 200 PARKAVE., P.O. BOX 677 FLORHAMPARK, NJ 07932 (US) (57) ABSTRACT The described invention provides kinase inhibiting composi (21) Appl. No.: 12/634,476 tions containing a therapeutic amount of a therapeutic inhibi (22) Filed: Dec. 9, 2009 torpeptide that inhibits at least one kinase enzyme, methods e 19 for treating an inflammatory disorder whose pathophysiology comprises inflammatory cytokine expression, and methods Related U.S. Application Data for treating an inflammatory disorder whose pathophysiology (60) Provisional application No. 61/121,396, filed on Dec. comprises inflammatory cytokine expression using the kinase 10, 2008. inhibiting compositions. 20 { ki> | 0: & c s - --- 33- x: SE PEPELE, ics 1.-- E- X K. AAA 22.9 --- KKK. Y.A., 3.2; C. -r { AAEASA. A. E. i : A X AAAAAAA; ; ; ; :-n. 4:-: is SEEKESAN.ARESA, 3523 -- -- Yili.A.R.AKA: 5,342 3. {{RCE: Rix i: Patent Application Publication US 2010/0158968A1 & ******** NO s ***** · Patent Application Publication Jun. 24, 2010 Sheet 2 of 11 US 2010/0158968A1 it, O Peptide: Cso: g E 100 WRRKAWRRKANRO, GWAA.
    [Show full text]
  • Identification of the Enzymatic Pathways of Nucleotide Metabolism in Human Lymphocytes and Leukemia Cells'
    [CANCER RESEARCH 33, 94-103, January 1973] Identification of the Enzymatic Pathways of Nucleotide Metabolism in Human Lymphocytes and Leukemia Cells' E. M. Scholar and P. Calabresi Department of Medicine, The Roger Williams General Hospital, Providence, Rhode Island 02908, and The Division of Biological and Medical Sciences,Brown University, Providence,Rhode Island 02912 SUMMARY monocytes, and lymphocytes, it is difficult to know in what particular fraction an enzyme activity is present. It would therefore be advantageous to separate out the different Extracts of lymphocytes from normal donors and from components of the leukocyte fraction before investigating patients with chronic lymphocytic leukemia (CLL) and acute their enzymatic activities. All previously reported work on the lymphoblastic leukemia were examined for a variety of enzymes of purine nucleotide metabolism was done at best in enzymes with activity for purine nucleotide biosynthesis, the whole white blood cell fraction. Those enzymes found to interconversion, and catabolism as well as for a selected be present included adenine and guanine phosphoribosyltrans number of enzymes involved in pyrimidine nucleotide ferase (2, 32), PNPase2 (7), deoxyadenosine deaminase (7), metabolism. Lymphocytes from all three donor types (normal, ATPase (4), and inosine kinase (21). CLL, acute lymphocytic leukemia) contained the following A detailed knowledge of the enzymatic pathways of purine enzymatic activities: adenine and guanine phosphoribosyl and pyrimidine nucleotide metabolism in normal lymphocytes transferase , adenosine kinase , nucieoside diphosphate kinase, and leukemia cells is important in elucidating any biochemical adenylate kinase, guanylate kinase, cytidylate kinase, uridylate differences that may exist. Such differences may be exploited kinase, adenosine deaminase, purine nucleoside phosphorylase, in chemotherapy and in gaining and understanding of the and adenylate deaminase (with ATP).
    [Show full text]
  • Aprtl, 1979 a Study of the Metabolisi4 of a Novel Dinuclioside Polyphosphatë (Hs3) Found in Mammalian Cills : Possiblt Regulat]On of Nucltic Ac]D Biosynthisis
    THE UI'IIVERS TTY OF MANITOBA A STUDY OF THE ù1ETABOLISM OF A NOVEI, DINUCLEOSIÐE POLYPHOSPHATE (HS3) FOUND IN ITAPIT4AL IAN CELLS: POSS]BLE REGULATTON OF TTUC],EÏC ACTD BIOSYNTHESÏS BY HS3 DURING STËP-DOWN GRO¡]TH CONDITIONS BY SI{EE HAN GOH A THES]S SUBI'IITTED TO THE FACULTY OF GR.ADUATE STUDIES IN PART]AL FULLFTLIqENT OF THE REOUTREUENTS FOR THE DEGREE OF DOCTOR OF PHTLOSOPHY . DEPARTMENT OF I{ICROBÏOI,OGY WTNNIPEG , 1UANTTOBA APRTL, 1979 A STUDY OF THE METABOLISI4 OF A NOVEL DINUCLIOSIDE POLYPHOSPHATË (HS3) FOUND IN MAMMALIAN CILLS : POSSIBLT REGULAT]ON OF NUCLTIC AC]D BIOSYNTHISIS BY HS3 DURING STEP.DOI,,IN GROWTH CONDITIONS. BY SI.IEE HAN GOH A dissertation slrbmitted to the Ftculty of Gradtrate Studies ol the University of Marlitoba in partial fulfillment of tlre requirerrrents ol the degree of DOCTOR OI. PI{ILOSOPHY o! 1979 Pemrission has bcen granted to the LIBRARY OF TIIE UNIVER- SITY OF MANITOBA to lend or sell copies of thìs dissertätion, to the NATIONAL LIIIRARY OF CANADA to microfilni this dissertation and to lend or sell copies of the film' and UNIVERSITY MICROFILMS to publish an abstrâct ol'this dissertation' 'l'lìc author reserves otlrer publicatiorr rights, and neither the dissertation nor extensive extracts frorìl it rnay be printed or other- wise reproduced witlìout the autl'ìor's writtell pernrission To Siew See and my parents Acknowledgements I would like to lhank Ðr. Herb B- LeJohn for his advice, interest and patience during the course of this research progranme. The friendship and. constructive criticisms of Linda, Renate, Dave, Glen, Rob and.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • Lymphospecific Toxicity in Adenosine Deaminase Deficiency and Purine
    Proc. Nati. Acad. Sci. USA Vol. 74, No. 12, pp. 5677-5681, December 1977 Immunology Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase(s) (immunodeficiency/lymphocyte/purine deoxyribonucleoside kinase/purine deoxyribonucleotides) DENNIS A. CARSON*, JONATHAN KAYE*, AND J. E. SEEGMILLERt *Division of Rheumatology, Department of Clinical Research, Scripps Clinic and Research Foundation, La Jolla, California 92037; and t Department of Medicine, University of California, San Diego, La Jolla, California 92037 Contributed by J. Edwin Seegmiller, September 26, 1977 ABSTRACT Inherited deficiencies of the enzymes adeno- deaminase deficiency by enzyme replacement in the form of sine deaminase (adenosine aminohydrolase; EC 3.5.4.4) and purine nucleoside phosphorylase (purine-nucleoside:ortho- erythrocyte transfusions (4). phosphate ribosyltransferase; EC 2.4.2.1) preferentially interfere Three biochemical mechanisms have been proposed to ex- with lymphocyte development while sparing most other organ plain the association of deaminase deficiency with immuno- systems. Previous experiments have shown that through the deficiency disease, i.e., adenosine-induced pyrimidine star- action of specific kinases, nucleosides can be "trapped" intra- vation (5), hypoxanthine deficiency (6), and adenosine-me- cellularly in the form of 5'-phosphates. We therefore measured diated elevations in cyclic AMP concentrations (7). In the ab- the ability of newborn human tissues to phosphorylate adeno- sine and deoxyadenosine, the substrate of adenosine deaminase, sence of further information, these hypotheses do not explain and also inosine, deoxyinosine, guanosine, and deoxyguanosine, the preferential impairment of lymphoid development seen the substrates of purine nucleoside phosphorylase. Substantial in both phosphorylase and deaminase deficiency.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0186358 A1 Melville Et Al
    US 200901 86.358A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0186358 A1 Melville et al. (43) Pub. Date: Jul. 23, 2009 (54) PATHWAYANALYSIS OF CELL CULTURE Related U.S. Application Data PHENOTYPES AND USES THEREOF (60) Provisional application No. 61/016,390, filed on Dec. 21, 2007. (75) Inventors: Mark Melville, Melrose, MA (US); Publication Classification Niall Barron, Shankill (IE): Martin Clynes, Clontarf (IE): (51) Int. C. CI2O I/68 (2006.01) Padraig Doolan, Swords (IE): CI2P 2L/00 (2006.01) Patrick Gammell, Naas (IE): C07K I4/00 (2006.01) Paula Meleady, Ratoath (IE) CI2O 1/02 (2006.01) CI2N I/2 (2006.01) Correspondence Address: CI2N 5/06 (2006.01) CHOATE, HALL & STEWART LLP CI2N 5/04 (2006.01) TWO INTERNATIONAL PLACE (52) U.S. Cl. .............. 435/6; 435/69.1:530/300; 435/29: BOSTON, MA 02110 (US) 435/252.3; 435/325; 435/419:435/254.2 (57) ABSTRACT (73) Assignees: Wyeth, Madison, NJ (US); Dublin The present invention provides methods for systematically City University, Glasnevin (IE) identifying genes, proteins and/or related pathways that regu late or indicative of cell phenotypes. The present invention further provides methods for manipulating the identified (21) Appl. No.: 12/340,629 genes, proteins and/or pathways to engineer improved cell lines and/or to evaluate or select cell lines with desirable (22) Filed: Dec. 19, 2008 phenotypes. inhibition of Signalling Signalling Caspases Apoptosis Apoptosis Signalling Caspases ATM Integrin MAPK p38 Signalling Signalling Signalling Signalling Signalling MAPK in ATM p53 Integrin Signalling Signalling Apoptosis Growth and Caspases Signalling Different.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • (Camellia Sinensis) and Coffee (Co¡Ea Arabica) Plants by Ribavirin
    FEBS 27819 FEBS Letters 554 (2003) 473^477 View metadata, citation and similar papers at core.ac.uk brought to you by CORE Inhibition of ca¡eine biosynthesis in tea (Camellia sinensisprovided) andby Elsevier - Publisher Connector co¡ee (Co¡ea arabica) plants by ribavirin Chaman Ara Keyaa, Alan Crozierb, Hiroshi Ashiharaa;c;Ã aDepartment of Advanced Bioscience, Graduate School of Humanities and Sciences, Ochanomizu University, Tokyo 112-8610, Japan b Plant Products and Human Nutrition Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK c Metabolic Biology Group, Department of Biology, Faculty of Science, Ochanomizu University, Tokyo 112-8610, Japan Received 3 September 2003; revised 30 September 2003; accepted 14 October 2003 First published online 27 October 2003 Edited by Marc Van Montagu enosyl-L-methionine cycle [12] and/or (ii) purine nucleotide Abstract The e¡ects of ribavirin, an inhibitor of inosine-5P- monophosphate (IMP) dehydrogenase, on [8-14C]inosine metab- biosynthesis de novo [13]. Since IMP appears to synergistical- olism in tea leaves, co¡ee leaves and co¡ee fruits were inves- ly improve the £avour of amino acid-based taste in humans tigated. Incorporation of radioactivity from [8-14C]inosine into [14], Koshiishi et al. [15] recently suggested that blocking purine alkaloids, such as theobromine and ca¡eine, guanine res- IMPDH and enhancing IMP levels may be a key step to idues of RNA, and CO2 was reduced by ribavirin, while incor- produce a ca¡eine-de¢cient tea with enhanced £avour. poration into nucleotides, including IMP and adenine residues of In the present study, we ¢rst examined ca¡eine biosynthesis RNA, was increased.
    [Show full text]
  • BMC Structural Biology Biomed Central
    BMC Structural Biology BioMed Central Research article Open Access A comprehensive update of the sequence and structure classification of kinases Sara Cheek2, Krzysztof Ginalski2,3, Hong Zhang2 and Nick V Grishin*1,2 Address: 1Howard Hughes Medical Institute, University of Texas Southwestern Medical Center 5323 Harry Hines Blvd., Dallas, Texas 75390, USA, 2Department of Biochemistry, University of Texas Southwestern Medical Center 5323 Harry Hines Blvd., Dallas, Texas 75390, USA and 3Bioinformatics Laboratory, Interdisciplinary Centre for Mathematical and Computational Modelling Warsaw University, Pawinskiego 5a, 02-106 Warsaw, Poland Email: Sara Cheek - [email protected]; Krzysztof Ginalski - [email protected]; Hong Zhang - [email protected]; Nick V Grishin* - [email protected] * Corresponding author Published: 16 March 2005 Received: 11 January 2005 Accepted: 16 March 2005 BMC Structural Biology 2005, 5:6 doi:10.1186/1472-6807-5-6 This article is available from: http://www.biomedcentral.com/1472-6807/5/6 © 2005 Cheek et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: A comprehensive update of the classification of all available kinases was carried out. This survey presents a complete global picture of this large functional class of proteins and confirms the soundness of our initial kinase classification scheme. Results: The new survey found the total number of kinase sequences in the protein database has increased more than three-fold (from 17,310 to 59,402), and the number of determined kinase structures increased two-fold (from 359 to 702) in the past three years.
    [Show full text]
  • Supplementary Material (ESI) for Natural Product Reports
    Electronic Supplementary Material (ESI) for Natural Product Reports. This journal is © The Royal Society of Chemistry 2014 Supplement to the paper of Alexey A. Lagunin, Rajesh K. Goel, Dinesh Y. Gawande, Priynka Pahwa, Tatyana A. Gloriozova, Alexander V. Dmitriev, Sergey M. Ivanov, Anastassia V. Rudik, Varvara I. Konova, Pavel V. Pogodin, Dmitry S. Druzhilovsky and Vladimir V. Poroikov “Chemo- and bioinformatics resources for in silico drug discovery from medicinal plants beyond their traditional use: a critical review” Contents PASS (Prediction of Activity Spectra for Substances) Approach S-1 Table S1. The lists of 122 known therapeutic effects for 50 analyzed medicinal plants with accuracy of PASS prediction calculated by a leave-one-out cross-validation procedure during the training and number of active compounds in PASS training set S-6 Table S2. The lists of 3,345 mechanisms of action that were predicted by PASS and were used in this study with accuracy of PASS prediction calculated by a leave-one-out cross-validation procedure during the training and number of active compounds in PASS training set S-9 Table S3. Comparison of direct PASS prediction results of known effects for phytoconstituents of 50 TIM plants with prediction of known effects through “mechanism-effect” and “target-pathway- effect” relationships from PharmaExpert S-79 S-1 PASS (Prediction of Activity Spectra for Substances) Approach PASS provides simultaneous predictions of many types of biological activity (activity spectrum) based on the structure of drug-like compounds. The approach used in PASS is based on the suggestion that biological activity of any drug-like compound is a function of its structure.
    [Show full text]
  • Springer Handbook of Enzymes
    Dietmar Schomburg Ida Schomburg (Eds.) Springer Handbook of Enzymes Alphabetical Name Index 1 23 © Springer-Verlag Berlin Heidelberg New York 2010 This work is subject to copyright. All rights reserved, whether in whole or part of the material con- cerned, specifically the right of translation, printing and reprinting, reproduction and storage in data- bases. The publisher cannot assume any legal responsibility for given data. Commercial distribution is only permitted with the publishers written consent. Springer Handbook of Enzymes, Vols. 1–39 + Supplements 1–7, Name Index 2.4.1.60 abequosyltransferase, Vol. 31, p. 468 2.7.1.157 N-acetylgalactosamine kinase, Vol. S2, p. 268 4.2.3.18 abietadiene synthase, Vol. S7,p.276 3.1.6.12 N-acetylgalactosamine-4-sulfatase, Vol. 11, p. 300 1.14.13.93 (+)-abscisic acid 8’-hydroxylase, Vol. S1, p. 602 3.1.6.4 N-acetylgalactosamine-6-sulfatase, Vol. 11, p. 267 1.2.3.14 abscisic-aldehyde oxidase, Vol. S1, p. 176 3.2.1.49 a-N-acetylgalactosaminidase, Vol. 13,p.10 1.2.1.10 acetaldehyde dehydrogenase (acetylating), Vol. 20, 3.2.1.53 b-N-acetylgalactosaminidase, Vol. 13,p.91 p. 115 2.4.99.3 a-N-acetylgalactosaminide a-2,6-sialyltransferase, 3.5.1.63 4-acetamidobutyrate deacetylase, Vol. 14,p.528 Vol. 33,p.335 3.5.1.51 4-acetamidobutyryl-CoA deacetylase, Vol. 14, 2.4.1.147 acetylgalactosaminyl-O-glycosyl-glycoprotein b- p. 482 1,3-N-acetylglucosaminyltransferase, Vol. 32, 3.5.1.29 2-(acetamidomethylene)succinate hydrolase, p. 287 Vol.
    [Show full text]